C-squared Pharma

Activities: Ingredients

Trending Articles

  1. Navigating AI Integration in medical device manufacturing: risks, requirements and best practices This article explores the regulatory, technical and strategic considerations associated with integrating AI into medical devices, highlighting SaMD classification, compliance...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. BASF announces up to 20% price increase on pharmaceutical excipients and selected APIs BASF Pharma Solutions has implemented an immediate global price adjustment of up to 20% across its pharmaceutical excipients and selected active pharmaceutical ingredients...
  4. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding...
  5. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now